25 XP   0   0   10

Alterity Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse Alterity Therapeutics Ltd together

PenkeI guess you are interested in Alterity Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alterity Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alterity Therapeutics Ltd

I send you an email if I find something interesting about Alterity Therapeutics Ltd.

Quick analysis of Alterity Therapeutics Ltd (30 sec.)










What can you expect buying and holding a share of Alterity Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$-0.01
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$-0.01
Return On Investment
-231.0%

For what price can you sell your share?

Current Price per Share
A$0.01
Expected price per share
A$0.004 - A$0.005
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Alterity Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)

A$0.01

Intrinsic Value Per Share

A$-0.06 - A$-0.04

Total Value Per Share

A$-0.05 - A$-0.03

2. Growth of Alterity Therapeutics Ltd (5 min.)




Is Alterity Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$14.9m$23.1m-$8.2m-55.5%

How much money is Alterity Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$9m-$8.4m-$627.3k-6.9%
Net Profit Margin-352.5%-513,882.4%--

How much money comes from the company's main activities?

3. Financial Health of Alterity Therapeutics Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#647 / 1050

Most Revenue
#897 / 1050

Most Profit
#573 / 1050

Most Efficient
#333 / 1050
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Alterity Therapeutics Ltd? (5 min.)

Welcome investor! Alterity Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of Alterity Therapeutics Ltd.

What can you expect buying and holding a share of Alterity Therapeutics Ltd?

First you should know what it really means to hold a share of Alterity Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Alterity Therapeutics Ltd is A$0.005. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alterity Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alterity Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alterity Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.00-41.2%0.00-41.2%0.00-38.3%0.00-40.4%0.00-33.0%
Usd Book Value Change Per Share0.00-37.8%0.00-37.8%0.0014.9%0.004.0%0.002.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-37.8%0.00-37.8%0.0014.9%0.004.0%0.002.6%
Usd Price Per Share0.00-0.00-0.01-0.01-0.04-
Price to Earnings Ratio-2.22--2.22--4.43--6.10--32.42-
Price-to-Total Gains Ratio-2.42--2.42-11.40-54.22-66.14-
Price to Book Ratio1.34-1.34-1.61-4.34-9.95-
Price-to-Total Gains Ratio-2.42--2.42-11.40-54.22-66.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0032695
Number of shares305857
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (305857 shares)-577.5261.44
Gains per Year (305857 shares)-2,310.09245.75
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2310-23200246236
20-4620-46300492482
30-6930-69400737728
40-9240-92500983974
50-11550-11560012291220
60-13861-13870014751466
70-16171-16180017201712
80-18481-18490019661958
90-20791-20800022122204
100-23101-23110024582450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.022.00.00.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%11.011.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.022.00.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%11.011.00.050.0%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Alterity Therapeutics Ltd

About Alterity Therapeutics Ltd

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-02-08 04:21:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Alterity Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alterity Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alterity Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -352.5% means that $-3.53 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alterity Therapeutics Ltd:

  • The MRQ is -352.5%. The company is making a huge loss. -2
  • The TTM is -352.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-352.5%TTM-352.5%0.0%
TTM-352.5%YOY-513,882.4%+513,529.9%
TTM-352.5%5Y-131,389.7%+131,037.1%
5Y-131,389.7%10Y-67,916.4%-63,473.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-352.5%-172.8%-179.7%
TTM-352.5%-221.6%-130.9%
YOY-513,882.4%-289.5%-513,592.9%
5Y-131,389.7%-489.6%-130,900.1%
10Y-67,916.4%-608.7%-67,307.7%
1.1.2. Return on Assets

Shows how efficient Alterity Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alterity Therapeutics Ltd to the Biotechnology industry mean.
  • -50.5% Return on Assets means that Alterity Therapeutics Ltd generated $-0.51 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alterity Therapeutics Ltd:

  • The MRQ is -50.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -50.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-50.5%TTM-50.5%0.0%
TTM-50.5%YOY-31.1%-19.5%
TTM-50.5%5Y-52.2%+1.6%
5Y-52.2%10Y-40.4%-11.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-50.5%-12.4%-38.1%
TTM-50.5%-12.1%-38.4%
YOY-31.1%-11.3%-19.8%
5Y-52.2%-13.7%-38.5%
10Y-40.4%-15.1%-25.3%
1.1.3. Return on Equity

Shows how efficient Alterity Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alterity Therapeutics Ltd to the Biotechnology industry mean.
  • -60.5% Return on Equity means Alterity Therapeutics Ltd generated $-0.61 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alterity Therapeutics Ltd:

  • The MRQ is -60.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -60.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-60.5%TTM-60.5%0.0%
TTM-60.5%YOY-36.2%-24.3%
TTM-60.5%5Y-62.4%+1.9%
5Y-62.4%10Y-47.0%-15.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-60.5%-15.8%-44.7%
TTM-60.5%-15.2%-45.3%
YOY-36.2%-14.2%-22.0%
5Y-62.4%-18.5%-43.9%
10Y-47.0%-19.7%-27.3%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Alterity Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alterity Therapeutics Ltd is operating .

  • Measures how much profit Alterity Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alterity Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of -390.4% means the company generated $-3.90  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alterity Therapeutics Ltd:

  • The MRQ is -390.4%. The company is operating very inefficient. -2
  • The TTM is -390.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-390.4%TTM-390.4%0.0%
TTM-390.4%YOY-714,390.1%+713,999.7%
TTM-390.4%5Y-171,495.1%+171,104.7%
5Y-171,495.1%10Y-88,200.0%-83,295.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-390.4%-288.2%-102.2%
TTM-390.4%-225.9%-164.5%
YOY-714,390.1%-293.2%-714,096.9%
5Y-171,495.1%-482.8%-171,012.3%
10Y-88,200.0%-607.6%-87,592.4%
1.2.2. Operating Ratio

Measures how efficient Alterity Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.74 means that the operating costs are $3.74 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alterity Therapeutics Ltd:

  • The MRQ is 3.738. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.738. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.738TTM3.7380.000
TTM3.738YOY6,054.929-6,051.191
TTM3.7385Y1,495.480-1,491.742
5Y1,495.48010Y772.789+722.691
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7382.938+0.800
TTM3.7383.314+0.424
YOY6,054.9293.856+6,051.073
5Y1,495.4806.009+1,489.471
10Y772.7897.532+765.257
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Alterity Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alterity Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.17 means the company has $6.17 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alterity Therapeutics Ltd:

  • The MRQ is 6.173. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.173. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.173TTM6.1730.000
TTM6.173YOY7.069-0.896
TTM6.1735Y7.003-0.830
5Y7.00310Y9.809-2.806
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1734.025+2.148
TTM6.1734.485+1.688
YOY7.0695.591+1.478
5Y7.0036.256+0.747
10Y9.8096.556+3.253
1.3.2. Quick Ratio

Measures if Alterity Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alterity Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 5.58 means the company can pay off $5.58 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alterity Therapeutics Ltd:

  • The MRQ is 5.577. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.577. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.577TTM5.5770.000
TTM5.577YOY6.792-1.215
TTM5.5775Y6.677-1.099
5Y6.67710Y9.608-2.931
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5773.664+1.913
TTM5.5774.164+1.413
YOY6.7925.485+1.307
5Y6.6776.122+0.555
10Y9.6086.377+3.231
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Alterity Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alterity Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alterity Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Alterity Therapeutics Ltd assets are financed with 16.5% credit (debt) and the remaining percentage (100% - 16.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alterity Therapeutics Ltd:

  • The MRQ is 0.165. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.165. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.165TTM0.1650.000
TTM0.165YOY0.142+0.022
TTM0.1655Y0.155+0.010
5Y0.15510Y0.121+0.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1650.331-0.166
TTM0.1650.328-0.163
YOY0.1420.262-0.120
5Y0.1550.370-0.215
10Y0.1210.380-0.259
1.4.2. Debt to Equity Ratio

Measures if Alterity Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alterity Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 19.7% means that company has $0.20 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alterity Therapeutics Ltd:

  • The MRQ is 0.197. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.197. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.197TTM0.1970.000
TTM0.197YOY0.166+0.031
TTM0.1975Y0.186+0.011
5Y0.18610Y0.141+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1970.375-0.178
TTM0.1970.395-0.198
YOY0.1660.319-0.153
5Y0.1860.428-0.242
10Y0.1410.469-0.328
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Alterity Therapeutics Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alterity Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare Alterity Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -2.22 means the investor is paying $-2.22 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alterity Therapeutics Ltd:

  • The EOD is -1.587. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.222. Based on the earnings, the company is expensive. -2
  • The TTM is -2.222. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.587MRQ-2.222+0.635
MRQ-2.222TTM-2.2220.000
TTM-2.222YOY-4.435+2.213
TTM-2.2225Y-6.102+3.880
5Y-6.10210Y-32.423+26.320
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.587-2.500+0.913
MRQ-2.222-2.208-0.014
TTM-2.222-2.771+0.549
YOY-4.435-4.423-0.012
5Y-6.102-6.089-0.013
10Y-32.423-6.214-26.209
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alterity Therapeutics Ltd:

  • The EOD is -1.093. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.531. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.531. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.093MRQ-1.531+0.437
MRQ-1.531TTM-1.5310.000
TTM-1.531YOY-4.585+3.054
TTM-1.5315Y-6.037+4.506
5Y-6.03710Y-28.917+22.880
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.093-3.280+2.187
MRQ-1.531-2.833+1.302
TTM-1.531-3.523+1.992
YOY-4.585-6.018+1.433
5Y-6.037-8.184+2.147
10Y-28.917-8.594-20.323
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alterity Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.34 means the investor is paying $1.34 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alterity Therapeutics Ltd:

  • The EOD is 0.961. Based on the equity, the company is cheap. +2
  • The MRQ is 1.345. Based on the equity, the company is underpriced. +1
  • The TTM is 1.345. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.961MRQ1.345-0.384
MRQ1.345TTM1.3450.000
TTM1.345YOY1.606-0.262
TTM1.3455Y4.344-2.999
5Y4.34410Y9.951-5.607
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9612.050-1.089
MRQ1.3451.842-0.497
TTM1.3452.099-0.754
YOY1.6063.053-1.447
5Y4.3443.544+0.800
10Y9.9513.828+6.123
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alterity Therapeutics Ltd.

3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Alterity Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.003-0.0030%0.001-353%0.000-1040%0.000-1532%
Book Value Per Share--0.0050.0050%0.008-36%0.005-2%0.006-14%
Current Ratio--6.1736.1730%7.069-13%7.003-12%9.809-37%
Debt To Asset Ratio--0.1650.1650%0.142+16%0.155+6%0.121+36%
Debt To Equity Ratio--0.1970.1970%0.166+19%0.186+6%0.141+40%
Dividend Per Share----0%-0%-0%-0%
Eps---0.003-0.0030%-0.003-7%-0.003-2%-0.003-20%
Free Cash Flow Per Share---0.005-0.0050%-0.003-38%-0.003-27%-0.003-41%
Free Cash Flow To Equity Per Share---0.005-0.0050%0.001-582%0.000-97%0.000-97%
Gross Profit Margin--1.0041.0040%1.000+0%1.001+0%1.0050%
Intrinsic Value_10Y_max---0.035--------
Intrinsic Value_10Y_min---0.058--------
Intrinsic Value_1Y_max---0.003--------
Intrinsic Value_1Y_min---0.004--------
Intrinsic Value_3Y_max---0.009--------
Intrinsic Value_3Y_min---0.014--------
Intrinsic Value_5Y_max---0.016--------
Intrinsic Value_5Y_min---0.026--------
Market Cap21913751.040-40%30679251.45630679251.4560%56975752.704-46%82395703.910-63%288823238.707-89%
Net Profit Margin---3.525-3.5250%-5138.824+145667%-1313.897+37170%-679.164+19165%
Operating Margin---3.904-3.9040%-7143.901+182906%-1714.951+43832%-882.000+22494%
Operating Ratio--3.7383.7380%6054.929-100%1495.480-100%772.789-100%
Pb Ratio0.961-40%1.3451.3450%1.606-16%4.344-69%9.951-86%
Pe Ratio-1.587+29%-2.222-2.2220%-4.435+100%-6.102+175%-32.423+1359%
Price Per Share0.005-40%0.0070.0070%0.013-46%0.019-63%0.066-89%
Price To Free Cash Flow Ratio-1.093+29%-1.531-1.5310%-4.585+200%-6.037+294%-28.917+1789%
Price To Total Gains Ratio-1.732+29%-2.424-2.4240%11.399-121%54.218-104%66.142-104%
Quick Ratio--5.5775.5770%6.792-18%6.677-16%9.608-42%
Return On Assets---0.505-0.5050%-0.311-39%-0.522+3%-0.404-20%
Return On Equity---0.605-0.6050%-0.362-40%-0.624+3%-0.470-22%
Total Gains Per Share---0.003-0.0030%0.001-353%0.000-1040%0.000-1532%
Usd Book Value--14917361.19514917361.1950%23192911.655-36%15151472.827-2%17249399.291-14%
Usd Book Value Change Per Share---0.002-0.0020%0.001-353%0.000-1040%0.000-1532%
Usd Book Value Per Share--0.0030.0030%0.005-36%0.003-2%0.004-14%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.002-0.0020%-0.002-7%-0.002-2%-0.002-20%
Usd Free Cash Flow---13106214.477-13106214.4770%-8125540.569-38%-9574691.124-27%-7669771.157-41%
Usd Free Cash Flow Per Share---0.003-0.0030%-0.002-38%-0.002-27%-0.002-41%
Usd Free Cash Flow To Equity Per Share---0.003-0.0030%0.001-582%0.000-97%0.000-97%
Usd Market Cap14329401.805-40%20061162.52720061162.5270%37256444.693-46%53878550.787-63%188861515.791-89%
Usd Price Per Share0.003-40%0.0050.0050%0.009-46%0.012-63%0.043-89%
Usd Profit---9028080.159-9028080.1590%-8400693.188-7%-8348061.300-8%-6969562.482-23%
Usd Revenue--2560890.1492560890.1490%1634.750+156553%531643.063+382%332312.961+671%
Usd Total Gains Per Share---0.002-0.0020%0.001-353%0.000-1040%0.000-1532%
 EOD+3 -5MRQTTM+0 -0YOY+7 -275Y+9 -2510Y+6 -28

4.2. Fundamental Score

Let's check the fundamental score of Alterity Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.587
Price to Book Ratio (EOD)Between0-10.961
Net Profit Margin (MRQ)Greater than0-3.525
Operating Margin (MRQ)Greater than0-3.904
Quick Ratio (MRQ)Greater than15.577
Current Ratio (MRQ)Greater than16.173
Debt to Asset Ratio (MRQ)Less than10.165
Debt to Equity Ratio (MRQ)Less than10.197
Return on Equity (MRQ)Greater than0.15-0.605
Return on Assets (MRQ)Greater than0.05-0.505
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Alterity Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.631
Ma 20Greater thanMa 500.005
Ma 50Greater thanMa 1000.005
Ma 100Greater thanMa 2000.006
OpenGreater thanClose0.005
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets27,318
Total Liabilities4,505
Total Stockholder Equity22,813
 As reported
Total Liabilities 4,505
Total Stockholder Equity+ 22,813
Total Assets = 27,318

Assets

Total Assets27,318
Total Current Assets27,049
Long-term Assets269
Total Current Assets
Cash And Cash Equivalents 15,774
Net Receivables 8,666
Inventory 2,570
Other Current Assets 40
Total Current Assets  (as reported)27,049
Total Current Assets  (calculated)27,049
+/-0
Long-term Assets
Property Plant Equipment 269
Long-term Assets  (as reported)269
Long-term Assets  (calculated)269
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,382
Long-term Liabilities123
Total Stockholder Equity22,813
Total Current Liabilities
Short-term Debt 107
Accounts payable 1,716
Other Current Liabilities 2,666
Total Current Liabilities  (as reported)4,382
Total Current Liabilities  (calculated)4,489
+/- 107
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt103
Other Liabilities 20
Long-term Liabilities  (as reported)123
Long-term Liabilities  (calculated)123
+/-0
Total Stockholder Equity
Common Stock213,971
Retained Earnings -195,131
Total Stockholder Equity (as reported)22,813
Total Stockholder Equity (calculated)18,840
+/- 3,972
Other
Capital Stock213,971
Cash and Short Term Investments 15,774
Common Stock Shares Outstanding 2,427,842
Current Deferred Revenue-107
Liabilities and Stockholders Equity 27,318
Net Debt -15,563
Net Invested Capital 22,813
Net Tangible Assets 22,813
Net Working Capital 22,667
Property Plant and Equipment Gross 729
Short Long Term Debt Total 210



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-30
> Total Assets 
199
1,837
20,876
22,287
17,591
16,341
41,164
22,199
10,427
7,721
11,723
4,597
6,801
9,011
7,342
17,074
41,641
41,834
33,725
25,281
18,726
19,910
13,305
33,586
41,363
27,318
27,31841,36333,58613,30519,91018,72625,28133,72541,83441,64117,0747,3429,0116,8014,59711,7237,72110,42722,19941,16416,34117,59122,28720,8761,837199
   > Total Current Assets 
0
0
0
0
3,755
3,649
29,565
22,033
10,325
7,673
11,619
4,491
6,708
8,932
7,256
16,983
41,549
41,744
33,657
25,250
18,655
19,861
13,233
33,489
41,144
27,049
27,04941,14433,48913,23319,86118,65525,25033,65741,74441,54916,9837,2568,9326,7084,49111,6197,67310,32522,03329,5653,6493,7550000
       Cash And Cash Equivalents 
0
0
4,470
6,855
3,587
3,454
29,401
21,366
10,020
7,408
11,243
4,305
5,227
8,838
5,636
13,347
34,167
34,910
28,594
21,885
15,236
14,400
9,197
28,116
34,807
15,774
15,77434,80728,1169,19714,40015,23621,88528,59434,91034,16713,3475,6368,8385,2274,30511,2437,40810,02021,36629,4013,4543,5876,8554,47000
       Short-term Investments 
0
0
0
0
0
0
0
0
42
46
0
0
0
0
0
0
0
153
0
44
10
0
0
0
0
0
00000104401530000000464200000000
       Net Receivables 
0
0
0
0
108
143
92
174
194
70
121
1
1
3
1,552
3,526
7,320
6,522
4,787
3,036
3,152
4,829
3,458
4,278
4,725
8,666
8,6664,7254,2783,4584,8293,1523,0364,7876,5227,3203,5261,55231112170194174921431080000
       Other Current Assets 
0
0
0
0
60
52
1
0
0
26
11
185
1,480
91
0
112
97
153
25
44
257
10
10
9
10
40
4010910102574425153971120911,480185112600152600000
   > Long-term Assets 
0
0
0
0
13,835
12,692
11,598
166
102
48
105
106
94
79
86
91
92
90
68
31
71
49
71
97
219
269
2692199771497131689092918679941061054810216611,59812,69213,8350000
       Property Plant Equipment 
0
0
0
0
140
141
180
166
102
48
69
71
59
41
48
47
48
45
24
31
71
49
71
97
219
269
2692199771497131244548474841597169481021661801411400000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
44
0
0
0
0
0
0
0
000000044000000000000000000
       Intangible Assets 
0
0
0
0
13,696
12,551
11,419
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000011,41912,55113,6960000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
35
35
35
38
38
44
0
0
44
0
71
49
-71
-97
-219
-269
-269-219-97-714971044004438383535350000000000
> Total Liabilities 
200
1,918
147
895
913
565
2,696
2,684
1,693
2,110
1,836
847
1,572
2,080
1,718
3,099
3,955
2,721
2,358
1,591
2,645
3,355
2,757
3,115
5,894
4,505
4,5055,8943,1152,7573,3552,6451,5912,3582,7213,9553,0991,7182,0801,5728471,8362,1101,6932,6842,6965659138951471,918200
   > Total Current Liabilities 
0
0
0
0
913
563
2,688
2,639
1,616
1,739
972
799
1,500
2,075
1,711
3,099
3,952
2,719
2,357
1,590
2,644
3,320
2,715
3,068
5,820
4,382
4,3825,8203,0682,7153,3202,6441,5902,3572,7193,9523,0991,7112,0751,5007999721,7391,6162,6392,6885639130000
       Short-term Debt 
0
0
0
0
0
0
0
0
42
46
0
0
0
286
299
803
0
153
0
44
10
33
33
28
58
107
10758283333104401530803299286000464200000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
362
312
65
1,334
1,694
954
1,449
2,689
1,716
1,7162,6891,4499541,6941,3346531236200000000000000000
       Other Current Liabilities 
0
0
0
0
70
24
42
78
192
77
121
0
0
356
88
68
98
12
0
22
1,310
1,626
1,760
1,619
-27
2,666
2,666-271,6191,7601,6261,310220129868883560012177192784224700000
   > Long-term Liabilities 
0
0
0
0
0
1
8
45
77
371
864
48
72
4
7
0
3
2
0
0
1
35
42
48
74
123
1237448423510023074724886437177458100000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
38
60
0
0603810000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
1
35
42
10
14
20
2014104235100200000000000000000
> Total Stockholder Equity
-1
-81
20,729
21,393
16,678
15,777
38,467
19,515
8,735
5,611
9,888
3,750
5,229
6,931
5,623
13,975
37,686
39,113
31,367
23,690
16,081
16,555
10,548
30,470
35,469
22,813
22,81335,46930,47010,54816,55516,08123,69031,36739,11337,68613,9755,6236,9315,2293,7509,8885,6118,73519,51538,46715,77716,67821,39320,729-81-1
   Retained Earnings 
0
0
0
0
-11,000
-15,533
-25,310
-50,268
2,869
4,106
-66,186
-73,567
-78,473
-84,905
-90,144
-97,931
-111,261
-117,146
-124,875
-122,648
-129,583
-141,237
-151,022
-169,728
-181,884
-195,131
-195,131-181,884-169,728-151,022-141,237-129,583-122,648-124,875-117,146-111,261-97,931-90,144-84,905-78,473-73,567-66,1864,1062,869-50,268-25,310-15,533-11,0000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-145
-230
14,573
14,602
-49,266
-52,472
6,081
-526
-330
9,495
9,633
10,527
8,937
9,363
9,363
2,320
1,754
1,159
866
2,751
3,566
0
03,5662,7518661,1591,7542,3209,3639,3638,93710,5279,6339,495-330-5266,081-52,472-49,26614,60214,573-230-1450000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,363
0
0
0
0
0
0
0
0
000000009,36300000000000000000
   Treasury Stock00000000000000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue3,916
Cost of Revenue-285
Gross Profit3,6313,631
 
Operating Income (+$)
Gross Profit3,631
Operating Expense-14,353
Operating Income-14,636-10,722
 
Operating Expense (+$)
Research Development13,199
Selling General Administrative4,937
Selling And Marketing Expenses51
Operating Expense14,35318,187
 
Net Interest Income (+$)
Interest Income16
Interest Expense--
Other Finance Cost-0
Net Interest Income16
 
Pretax Income (+$)
Operating Income-14,636
Net Interest Income16
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-13,702-15,288
EBIT - interestExpense = -15,288
-13,702
-13,807
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-15,288-13,702
Earnings Before Interest and Taxes (EBITDA)-15,186
 
After tax Income (+$)
Income Before Tax-13,702
Tax Provision-104
Net Income From Continuing Ops-13,807-13,807
Net Income-13,807
Net Income Applicable To Common Shares-13,807
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses14,353
Total Other Income/Expenses Net652-16
 

Technical Analysis of Alterity Therapeutics Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alterity Therapeutics Ltd. The general trend of Alterity Therapeutics Ltd is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alterity Therapeutics Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alterity Therapeutics Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.005 < 0.005 < 0.005.

The bearish price targets are: 0.004 > 0.004 > 0.004.

Tweet this
Alterity Therapeutics Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alterity Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alterity Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alterity Therapeutics Ltd. The current macd is -0.00014695.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alterity Therapeutics Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Alterity Therapeutics Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Alterity Therapeutics Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1